Dothan – Enrolling Now

  1. Boreas, “A randomized, double-blind, placebo-controlled, parallel-group, 52-week pivotal study to assess the efficacy, safety, and tolerability of Dupilumab in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with Type 2 inflammation.”

    We need volunteers who have experienced at least two flare-ups (exacerbations) of COPD within the past 12 months in spite of taking long acting respiratory inhalers. This study is evaluating an injection therapy as a possible means of reducing the frequency of COPD exacerbations.

  2. Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease

    Looking for individuals with history of heart attack, stroke, or vascular disease requiring surgery or stent for a one visit study checking your lipid profile.

  3. A randomized, double-blind, placebo-controlled, parallel group, multicenter, Phase 2a study to explore efficacy and safety of tezepelumab in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) COURSE)

    This study is a one year study examining whether an injection therapy can reduce the frequency of COPD exacerbations (flare-ups) in individuals suffering with frequent exacerbations in spite of taking long acting inhaler therapies. Eligibility requires compliance with your long acting inhalers for 12 months.

  4. A multi-center, randomized, double-blind, parallel-group, placebo-controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and characterized by eosinophil levels

    This study is a one year study examining whether an injection therapy can reduce the frequency of COPD exacerbations (flare-ups) in individuals suffering with frequent exacerbations in spite of taking long acting inhaler therapies. Eligibility requires compliance with your long acting inhalers for 12 months, and elevated levels of eosinophils in the blood.